Asymchem Laboratories, a pharmaceutical CDMO, has officially opened its new European development and pilot manufacturing site in Kent, UK.
The site is the company's first manufacturing plant to serve the European market, and is the former small molecule facility owned by Pfizer in Kent's Discovery Park.
The opening was marked by a ribbon cutting, which was performed by Asymchem's Chair, founder and CEO, Dr Hao Hong.
The small molecule facility now employs 70 team members on-site in the R&D labs, as well as the API pilot plant — a number of which are legacy Pfizer employees.
The company also plans to hire a number of other professionals throughout the rest of the year, as the pilot plant's operations continue to expand.
The facility will have equipment available for the manufacture of peptides and oligonucleotides, while also providing sustainable solutions for continuous flow and biocatalysis by 2025.
Hong said: “This is an exciting milestone for Asymchem to meet growing demand for pharma services and supply.”
CEO of Discovery Park, Mayer Schreiber, said: “We are thrilled to see Asymchem join our community at Discovery Park. We believe Kent is the ideal location for a European HQ, providing fast connections to both Europe and the capital, along with all important space to grow. Many of the team members at Asymchem have been working at Discovery Park for decades, and we’re delighted to continue to support and champion the talent here.”
